View Post

Research to remove exclusions on immunotherapy

In Clinical Trials by Barbara Jacoby

By: Michael Hardy From: mdanderson.org People used to ask Patrick Hwu, M.D., why he decided to devote his career to melanoma, a skin cancer with high mortality rates and limited treatment options. “They would come up to me and say, ‘How can you treat advanced melanoma? Isn’t that depressing?’ And actually, it was — my clinic of advanced melanoma patients …

View Post

Researchers identify potential target for new breast cancer treatments

In In The News by Barbara Jacoby

Source: https://www.kcl.ac.uk From: news-medical.net Researchers from the School of Basic & Medical Biosciences have identified a potential target that could lead to new treatments for triple negative breast cancer. One in five patients with breast cancer are diagnosed with triple negative breast cancer, a cancer type where tumour cells don’t have receptors for oestrogen and progesterone, or the Her2 protein. …

View Post

New clinical trials at Roswell Park build on virus research for innovative immunotherapy approach

In Clinical Trials by Barbara Jacoby

By: Katie Alexander From: www.wivb.com The Roswell Park Comprehensive Cancer Center is once again on the cutting-edge of research to find new cures, and Western New Yorkers could play a big role as clinical trials open for an innovative new approach to immunotherapy. Over the decades, there has been a lot of progress for certain types of cancers with immunotherapies, …

View Post

Birmingham-Based Southern Research Introduces Transgenic Mouse Model in Support of Immuno-Oncology Therapeutic Development

In In The News by Barbara Jacoby

Southern Research – the Birmingham-based research organization specializing in drug discovery, drug development, engineering, energy and the environment– has announced the Transgenic Mouse Human PD-1/L1 Model, its newest service offering in support of immuno-oncology (IO) therapeutic development. This model could help speed the development of new cancer therapies by targeting a key checkpoint inhibitor of medicines already on the market that activate …

View Post

Immunotherapy Pioneers at Children’s Hospital of Philadelphia Unveil Updated Efficacy Data of Single Infusion of Tisagenlecleucel, plus …

In In The News by Barbara Jacoby

… First-of-Its-Kind Checkpoint Inhibitor Research to Boost Response of CAR T-cell Gene Immunotherapy From: prnewswire.com Physician-scientists from Children’s Hospital of Philadelphia (CHOP) presented updated efficacy and safety data on Kymriah(R)* (tisagenlecleucel, formerly CTL019) –the first-ever U.S. Food and Drug Administration (FDA) approved personalized CAR T-cell gene immunotherapy for aggressive blood cancers at the 60th American Society of Hematology (ASH) annual meeting, …

View Post

Immunotherapy Expands Treatment Options for Metastatic Bladder Cancer

In Clinical Trials by Barbara Jacoby

By: Danielle Ternyila From: targetedonc.com Several recent updates from clinical trials are transforming the treatment landscape for urothelial carcinoma across a variety of subtypes. The use of immunotherapy, in particular, provides patients who progress after standard platinum-based chemotherapy with new hope and a plethora of options. In the metastatic setting, there have been 5 immune checkpoint inhibitors approved by the …

View Post

Targeting Innovation in Small Cell Lung Cancer

In Clinical Trials by Barbara Jacoby

By: Heather Stringer From: curetoday.com After consulting multiple doctors about her ongoing cough and congestion, LeeAnn Devore asked one of her physicians if she might have lung cancer. “He said the symptoms weren’t right,” says Devore, 66, of Magnolia, Texas. Three X-rays in five months confirmed that she had pneumonia in her right lung, yet she wasn’t responding to traditional …

View Post

FREE Immunotherapy Patient Summit – Houston, Sat, December 8, 2018

In Clinical Trials by Barbara Jacoby

From: CANCER RESEARCH INSTITUTE Date and Time:  Sat, December 8, 2018 – 10:00 AM – 3:30 PM PDT Hosted at MD Anderson Cancer Center Dan L. Duncan Cancer Prevention Building, (CPB) – 8th Floor Conference Center 1155 Pressler Street Houston, TX 77030 Learn about the basics of cancer immunotherapy, a highly promising new approach to cancer treatment. Medical experts along with …

View Post

FREE Immunotherapy Patient Summit – Houston, Sat, December 8, 2018

In In The News by Barbara Jacoby

From: CANCER RESEARCH INSTITUTE Date and Time:  Sat, December 8, 2018 – 10:00 AM – 3:30 PM PDT Hosted at MD Anderson Cancer Center Dan L. Duncan Cancer Prevention Building, (CPB) – 8th Floor Conference Center 1155 Pressler Street Houston, TX 77030 Learn about the basics of cancer immunotherapy, a highly promising new approach to cancer treatment. Medical experts along with …

View Post

9 things to know about CAR T-cell therapy

In Clinical Trials by Barbara Jacoby

By: Cynthia DeMarco From: mdanderson.org CAR T-cell therapy is a new type of cancer treatment offered at MD Anderson through clinical trials and FDA-approved standard of care cell therapy products. But what exactly is CAR T-cell therapy? And who should consider it? We spoke with Sattva Neelapu, M.D., to learn more. Here’s what he had to say. Let’s start with the …